PTC Therapeutics(PTCT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results – Strong revenue performance of $190 million – – Positive CHMP opinion for Sephience™ (sepiapterin) received in April 2025, NDA review remains on track for July 29, 2025 PDUFA date – – Global Sephience launch activities progressing well – – Strong cash position of over$2.0 billion as of March 31, 2025 – WARREN, N.J., May 6, 2025 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update ...